EARLY PD-L1 TESTING FOR M/uR HNSCC
Optimise multidisciplinary team decision-making
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
KEYTRUDA® (pembrolizumab) as monotherapy is indicated for the first-line treatment of metastatic or unresectable recurrent (M/uR) HNSCC in adults whose tumours express PD-L1 with a CPS ≥1.1
By including PD-L1 testing in your diagnostic bundle when you suspect or detect unresectable recurrent HNSCC, you can help to expand your patients’ treatment options at the next MDT meeting.1
How many of your patients could be PD-L1 positive?
In the KEYNOTE-048 study
of treatment-naïve M/uR HNSCC patients had tumours that expressed PD-L1 (CPS ≥1)1,2
n = 754/882; PD-L1 CPS was determined using the PD-L1 IHC 22C3 PharmDx assay
(Agilent Technologies, Carpinteria, CA, USA)1,2
MDT meetings are often time-limited so it is important to have all relevant patient information available for discussion, including investigational results, to ensure that all suitable treatment options can be considered.3,4
PD-L1 results available for review during MDT meetings could:
Improve MDT meeting effectiveness3,4
Avoid delays in treatment decisions due to incomplete information3,4
Broaden and personalise your patients’ treatment options1
EHNS/ESMO/ESTRO guidelines recommend PD-L1 testing for M/uR HNSCC to achieve personalised treatment for patients that may be eligible for 1L KEYTRUDA.5
At patient review
Consider including PD-L1 testing in your diagnostic bundle for suspected unresectable recurrent HNSCC1
At your MDT meeting
For patients whose tumours express PD-L1 CPS ≥ 1, KEYTRUDA could be considered as a treatment option1
KEYTRUDA as monotherapy is indicated for the first-line treatment of metastatic or unresectable recurrent (M/uR) HNSCC in adults whose tumours express PD-L1 with a CPS ≥1.1
Please refer to the Summary of Product Characteristics for further information before making any prescribing decisions.
1L = First-line; CPS = Combined Positive Score; EHNS = European Head & Neck Society; ESMO = European Society for Medical Oncology; ESTRO = European Society for Radiotherapy and Oncology; HNSCC = Head And Neck Squamous Cell Carcinoma; IHC = Immunohistochemistry; MDT = Multidisciplinary Team; M/uR = Metastatic Or Unresectable Recurrent; PD-L1 = Programmed Cell Death Ligand-1.
- KEYTRUDA Summary of Product Characteristics.
- Burtness B et al. Lancet. 2019:394;1915–28.
- Cancer Research UK. Meeting Patients’ Needs: Improving the effectiveness of multidisciplinary team meetings in cancer services. 2020. Available at: https://www.cancerresearchuk.org/sites/default/files/full_report_meeting_patients_needs_improving_the_effectiveness_of_multidisciplinary_team_meetings_.pdf
- Jalil R et al. Int J Surg. 2013;11:389–94.
- Machiels J-P et al. Ann Oncol. 2020;31(11):1462–1475.
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website